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Abstract - Duchenne and Becker muscular dystrophy (DMD/BMD) are severe X-linked neuromuscular disorders caused 
by mutations in the dystrophin gene. Our aim was to optimize a quantitative real-time PCR method based on SYBR® 
Green I chemistry for routine diagnostics of DMD/BMD deletion carriers. Twenty female relatives of DMD/BMD patients 
with previously detected partial gene deletions were studied. The relative quantity of the target exons was calculated by 
a comparative threshold cycle method (ΔΔCt). The carrier status of all subjects was successfully determined. The gene 
dosage ratio for non-carriers was 1.07±0.20, and for carriers 0.56±0.11. This assay proved to be simple, rapid, reliable and 
cost-effective. 
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INTRODUCTION
Duchenne and Becker muscular dystrophies (DMD 
and  BMD)  are  X-linked  neuromuscular  disorders 
with incidences of 1:3500 and 1:30000 male births, 
respectively  (Emery,  1991).  DMD  and  BMD  are 
caused by mutations in the dystrophin gene (DMD 
gene) located at the Xp21.2 region. Approximately 
65-70% of DMD and 85% of BMD patients show in-
tragenic deletions of one or several exons of the gene. 
Most of the mutations are located at the proximal 
(exon 3-7) and central (exon 45-52) regions of the 
gene  (Prior,  2005;  Hu,  1990;  http://www.umd.be). 
These regions are known as “deletional hotspots”. A 
small proportion of the mutations (6%) involve du-
plications and in the remaining DMD/BMD cases, 
the disease emerges as a result of small mutations, 
including point mutations or microdeletions/inser-
tions (Hu et al., 1988; Nishino, 2002). Mutations ei-
ther are inherited from asymptomatic female carriers 
(70%), occur de novo or arise from germline mosai-
cism (30%) (Worton, 1988).
Due  to  the  X-linked  nature  of  the  disorders, 
males carrying the mutated gene are affected, and 
females are the carriers of the disease. The absence 788 NELA MAKSIMOVIC ET AL.
of an efficient treatment for these progressive disor-
ders makes the determination of carrier status very 
important  for  genetic  counseling  and  prevention 
of the disease. Multiplex PCR technique has been 
widely used for the detection of common deletions 
in affected males (Beggs et al., 1990; Chamberlain et 
al., 1988). However, carrier identification in asymp-
tomatic female relatives of deletional DMD/BMD 
probands is still difficult due to the presence of both 
normal and mutant copies of the gene. During the 
past  decades,  several  biochemical  and  molecular 
methods have been developed in order to overcome 
this problem. Such methods include the measure-
ment of the serum creatinine phosphokinase (CPK) 
level,  immunohistochemical  methods  (Panigarhi, 
2001), DNA-based linkage analysis (Clemmens et 
al., 1991), Southern blotting (Den Dunnen et al., 
1989), fluorescent in situ hybridization (FISH) (Li-
gon et al., 2000) and reverse transcriptase-polymer-
ase chain reaction (RT-PCR) (Roberts et al., 1991). 
All these approaches are time-consuming and may 
suffer  from  limited  sensitivity.  Recently,  multi-
plex ligation-dependent probe amplification assay 
(MLPA) (Gatta et al., 2005), multiplex amplifiable 
probe hybridization assay (MAPH) (White et al., 
2002)  and  quantitative  real-time  PCR  have  been 
suggested as alternative methods to the current di-
agnostic approaches.
In the present study, we have optimized the quan-
titative real-time PCR assay based on SYBR® Green 
chemistry for determining the dosage of DMD gene 
exons 6, 47, 52 for direct DMD/BMD carrier detec-
tion. Quantitative real-time PCR is a high precision 
approach for gene dosage studies that displays digital 
data corresponding to the changes at gene level (Wil-
helm, 2003; Nosaeid, 2009; Ruiz-Ponte et al., 2006). 
MATERIALS AND METHODS
Patients
Blood samples were obtained from 2 unrelated ob-
ligate female carriers (characterized by two affected 
DMD sons in one case and by affected BMD father 
in the other) and 18 possible carriers from 9 fami-
lies with sporadic cases (characterized by only one 
affected son or brother). Affected males had partial 
dystrophin gene deletions involving either exon 6, 47 
or 52, previously detected by multiplex PCR. In par-
allel, normal female controls were used as wild-type 
reference. Informed written consents were obtained 
from all individuals participating in this study. 
DNA extraction
Genomic DNA was extracted from 5ml peripheral 
blood by standard salting-out (Miller et al., 1988). 
The concentration and purity of the isolated DNA 
were  determined  by  measuring  the  absorbance  at 
260 and 280 nm. DNAs were diluted in distilled wa-
ter to acquire a concentration of 6 ng/µl.
Real-time quantitative PCR
The sequences of primers used for amplification of 
exons 6, 47 and 52 were as published on the Leiden 
muscular dystrophy pages (http://dmd.nl). The real-
time PCR amplifications were carried out in optical 
grade  96-well  plates  (Microamp.  Applied  Biosys-
tems, USA) in a 15 µl reaction volume including 13.8 
µl SYBR® Green Master mix (Fermentas, Germany), 
0.6 µl of each primer and 6 ng of DNA. All samples 
were analyzed in duplicate for both reference and 
test exon. For each sample, one of the unaffected 
dystrophin gene exons was used as an endogenous 
control. In each assay normal control and no-tem-
plate control were included. PCR reactions were per-
formed on the 7500 real-time PCR system (Applied 
Biosystems,  USA)  using  the  following  conditions: 
preincubation 10 min at 95°C, followed by 40 cycles 
of denaturation at 95°C for 15 sec and annealing and 
elongation step at 64°C for 1 min. Each complete 
amplification stage was followed by a dissociation 
stage at 95°C for 15sec, 60°C for 1 min, and then the 
temperature was ramped up to 95°C. Fluorescence 
intensity was measured once per cycle at the end of 
the elongation phase. Amplification was followed by 
melting curve analysis performed according to the 
dissociation stage data (Liu et al., 2006). Reactions 
with a single peak at expected Tm were considered 
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Data analysis
Data evaluation was performed using the 7500 data 
analysis software (version 3.5) and Microsoft Excel. 
Quantitative analysis was performed by comparative 
Ct. The Ct parameter is defined as the cycle number 
at which the amplification plot passes a fixed thresh-
old. Mean Ct was the mean Ct value of duplicate 
amplification. ΔCt was calculated as the difference 
between the Ct values of the DMD test exon (exonA) 
and reference exon (exonB). ΔΔCt values for each 
tested individual were calculated using ΔCts of the 
healthy female as a calibrator following the equation:   
ΔΔCtexonA-exonB=(ΔCtexonA-exonB) targetsample-(ΔCtexonA-
exonB) calibrator. The relative fold increase (R) in exon 
quantity in the tested person was calculated using 
the equation: RexonA/exonB=2-(ΔΔCtexonA-exonB) (Livak, 2001). 
Using this method, a ΔΔCt ratio is expected to be 
about 1 in normal controls, about 0.5 in the females 
that are carriers of the deletion and 1.5 in females 
that are carriers of the duplication. 
Optimization and validation of real-time PCR assay
In order to validate the ΔΔCt method for the relative 
quantification of exons 6, 47 and 52, genomic DNA 
(gDNA) was isolated from the blood of a healthy fe-
male and 2-fold serial dilutions ranging from 50 to 
3.125 ng/µl were generated (50, 25,12.5, 6.25, 3.125 
ng/µl). For each dilution, three different PCR reac-
tions were set up. Each reaction contained a pair of 
primers specific for one of the three exons of interest, 
and was run in duplicate. The ΔCt values for each 
exon pair were calculated (Ctexon6-Ctexon47, Ctexon6-Ctex-
on52, Ctexon47-Ctexon52) and plotted against the logarithm 
of the amount of gDNA in each dilution. Afterwards, 
trend lines were drawn using Excel software (Micro-
soft).
RESULTS
Real-time  PCR,  based  on  SYBR® G r e e n  I  c h e m -
istry was optimized for the detection of deletions 
of exons 6, 47 and 52 within the dystrophin gene. 
In order to assess the validity of this comparative 
threshold cycle method for relative quantification, 
standard curves for target and reference exons were 
prepared over serially diluted genomic DNA sam-
ples.  The  mean  Ct  values  corresponding  to  each 
concentration  were  plotted  against  the  log  input 
of DNA. Trend line slopes were within an accept-
able range (-0.1< slope< 0.1), the PCR efficiencies 
of the target and the reference exons were approxi-
mately equal, which was a prerequisite for the ac-
curate copy number assessment (Fig. 1). To observe 
the presence of any possible primer dimer or non-
specifically  amplified  product  formation,  which 
Fig.  1  Validation  of  the  ΔΔCt  method  for  the  rela-
tive  quantification  of  exons  6,  47  and  52.  The  equa-
tions  of  the  trend  lines  are:  Ex6-52:  y=-0,038X+0,459;   
Ex 47-52: y= -0,066+0,774; Ex47-6: y=-0,060+0,937.
Fig. 2 Melting curve analysis of real-time PCR for DMD exons 
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usually creates additional peaks separate from the 
specific amplicon, dissociation curve analysis was 
performed for each amplification reaction. Results 
(single PCR product without any amplification of 
non-specific products is seen as one single sharp 
peak on the melting curve or one single band on 
agarose gels) showed that no detectable non-specif-
ic products were present in the reactions (Fig. 2). 
The duplicate runs of the exons of interest showed 
an almost complete overlap of parallel amplification 
plots (for all samples, the SD of Ct value was very 
low range) (Fig. 3). In total, samples from 20 indi-
viduals with known or unknown carrier status were 
tested using real-time PCR. The deletions of target 
exons were confirmed in 2 obligatory carriers and 8 
out of 18 (44.44%) of suspected carriers. The gene 
dosage ratio (R) for non-carriers was 1.07 ± 0.20 
and for carriers 0.56 ± 0.11. The ratio ranges be-
tween carriers and non-carriers of the deletions did 
not overlap, allowing the accurate discrimination of 
deletion carriers and normal individuals. 
DISCUSSION
Due to the lack of efficient rehabilitation and treat-
ment of progressive muscular dystrophy, counseling 
and prenatal diagnosis are the only available options 
nowadays. However, molecular diagnosis and car-
rier analysis of DMD/BMD is still difficult due to 
the size of the dystrophin gene, mutation diversity 
and the presence of a normal allele in female carri-
ers. The aim of this study was to develop a rapid and 
reliable real-time assay for direct DMD/BMD carrier 
detection that in the future may be used for routine 
diagnostics. We selected exons 6, 47 and 52 of the 
dystrophin gene since they are located in two mu-
tational hotspots of this gene. The assay is based on 
SYBR® Green I chemistry. The possibility that SYBR® 
Green I dye generated false positive signals due to 
its binding to nonspecific double stranded DNA was 
ruled out by performing melting curve analysis or gel 
electrophoresis of the PCR products. Using real-time 
PCR assay the carrier status of all subjects was suc-
cessfully determined. The gene dosage ratio ranges 
did not overlap, allowing the accurate discrimination 
of carriers and non-carriers. However, we had access 
only to carriers of the deletions, so it has yet to be 
assessed whether the assay is able to determine the 
duplication carriers’ status.
In our study, we did not choose an endogenous 
control outside the dystrophin gene. Instead, one of 
the unaffected dystrophin gene exons was used to 
quantify the other exon. This offered the possibility 
of internal quality control in diagnostics after the 
identification of a deletion and a different combina-
tion of test and reference exon for confirmation of 
the results (Joncourt et al., 2004). 
Multiplex end-point PCR approaches such as 
MAPH, MLPA and EPFA, can be effectively used 
for the rapid screening of deletions and duplications 
in the entire DMD coding region in both affected 
males and female carriers (Traverso et al., 2006). 
Once the mutation is known, real-time assay allows 
rapid identification of carrier status in a single PCR 
within few hours. Furthermore, the results obtained 
by end-point PCR could be confirmed by using an 
independent set of primers. Thus, a combination of 
these different assays may provide secure and cor-
rect diagnosis of DMD/BMD. 
SYBR® Green-based real-time PCR is highly sen-
sitive, specific and reproducible, requires a minimal 
Fig. 3 Amplification curve analysis for DMD exons 6, 47 and 
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quantity of DNA and is carried out in a single step 
(Traverso et al., 2006). The simplicity of the protocol 
allows its easy implementation in diagnostic labora-
tories. For routine application of this technique in 
the diagnosis of DMD/BMD it is necessary to devel-
op additional assays for the analysis of other exons 
frequently involved in DMD rearrangements. Fur-
thermore, it may be easily adapted for the screening 
of other genetic diseases that caused by deletions and 
duplications.
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